Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

Immune mediators as predictive biomarkers for anti-PD-1 antibody therapy in urothelial carcinoma

Introduction: This study aimed to identify immune mediators, including cytokines, chemokines, and growth factors, in the plasma for predicting treatment efficacy and immune-related adverse events (irAEs) in advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitors (ICIs).Methods:...

Full description

Bibliographic Details
Main Authors: Yosuke Shibata, Takeshi Kishida, Taku Kouro, Feifei Wei, Yuka Igarashi, Hidetomo Himuro, Takeaki Noguchi, Mitsuyuki Koizumi, Takahisa Suzuki, Kimito Osaka, Yusuke Saigusa, Tetsuro Sasada
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Pharmacology
Subjects:
immune checkpoint inhibitors
anti-PD-1 antibody
pembrolizumab
cytokine
chemokine
immune-related adverse event
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1269935/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1269935/full

Similar Items